FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385705989> ?p ?o ?g. }

• W4385705989 endingPage "e813564b" @default.
• W4385705989 startingPage "e813564b" @default.
• W4385705989 abstract "Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: High dose-intensive or infusional low-dose immunochemotherapy is a very effective treatment for Burkitt lymphoma (BL) irrespective of human immunodeficiency virus (HIV) infection. However, toxicities of these regimens are relevant. Dose reduction of chemotherapy after complete metabolic response (CMR) achievement could reduce toxicity without impact on outcome. Aims: The objective of the BURKIMAB14 trial (NCT05049473) was to evaluate the feasibility and outcome of young adults with BL after reduction of chemotherapy after CMR and to compare with those of similar patients (pts) included in the former BURKIMAB08 trial (Ribera JM, et al. Cancer. 2013; 119:1660-8), in which there was no dose reduction after CMR. Methods: Adult pts aged 18-55 yrs. were treated with Rituximab and intensive chemotherapy blocks according to the stage. Pts with localized stage (I, II non-bulky) received 4 cycles (A, B, C and A) and pts in advanced stage (II with bulky disease or III-IV) received 6 cycles (A, B, C, A, B, C). CNS prophylaxis consisted of TIT (methotrexate, cytarabine and hydrocortisone) administered in the pre-phase and twice in each cycle A and B, for a total of 9 doses in all pts. After completion of chemotherapy, CMR pts in advanced stages received two additional doses of rituximab. Compared with the BURKIMAB08 trial, in the BURKIMAB14 trial, IV methotrexate for cycles A, B and C was reduced 33% (1500 mg/m2 to 1000 mg/m2), iphosphamide was reduced 28% in cycle A (800 mg/m2 to 500 mg/m2) and cytarabine was reduced 25% in cycle C (2000 mg/m2 to 1500 mg/m2). Results: Sixty-eight pts aged 18-55 yrs. (median 39, 55 males) were included in the trial. Stage was localized in 21 pts (31%) and advanced in 47 (69%). 17 pts (25%) had HIV infection. CNS was involved in 10 pts (15%). Burkitt’s leukemia (>20% Burkitt cells in bone marrow) was observed in 19 pts (28%). Bulky mass (>10 cm) was present in 24/65 pts (37%). BL-IPI risk distribution (evaluable in 66 pts): low 16 (24%), intermediate 21 (32%) and high 29 (44%). Three patients discontinued the study before response evaluation, early death occurred in 1, resistance in 4 (6%) and CMR was attained in 60 (88%). 3 pts dead in remission and 5 relapsed. With a median follow-up (range) of 3.61 (0.1-7.42) yrs., the 4-yr OS probability was 82% (95%CI, 70% - 90%). Compared with the BURKIMAB08 trial no differences were observed in response to therapy and survival (4-yr OS in BURKIMAB08 trial 72% [95%CI, 61% - 80%], Figure 1). Regarding toxicity there was a significant reduction in the median duration of thrombocytopenia (6 days vs. 3 days, p=0.013), in the number of grade 3-4 infections (74/87 [85%] vs. 45/65 [69%], p= 0.019), and in the deaths by infection (12 [14%] vs. 2 [3%], p=0.019). Conclusion: The results of BURKIMAB14 in young adults are similar to those of other dose-intensive immunochemotherapy trials. Dose reduction of chemotherapy after CMR achievement decreased toxicity and did not have impact on outcome. Funding: Supported in part by the grant 2021 SGR 00771, AGAUR, Generalitat de Catalunya, Spain. Figure 1. Overall survival of pts in the BURKIMAB14 and BURKIMAB08 trials.Keywords: Treatment, Burkitt’s lymphoma, Young adult, Reduced intensity" @default.
• W4385705989 created "2023-08-10" @default.
• W4385705989 creator A5001976783 @default.
• W4385705989 creator A5003682435 @default.
• W4385705989 creator A5005934312 @default.
• W4385705989 creator A5012303177 @default.
• W4385705989 creator A5018422609 @default.
• W4385705989 creator A5022583155 @default.
• W4385705989 creator A5023787291 @default.
• W4385705989 creator A5026012894 @default.
• W4385705989 creator A5027810280 @default.
• W4385705989 creator A5027815550 @default.
• W4385705989 creator A5028097465 @default.
• W4385705989 creator A5032225567 @default.
• W4385705989 creator A5034654830 @default.
• W4385705989 creator A5037711823 @default.
• W4385705989 creator A5041166124 @default.
• W4385705989 creator A5047316683 @default.
• W4385705989 creator A5048507239 @default.
• W4385705989 creator A5052872662 @default.
• W4385705989 creator A5058982311 @default.
• W4385705989 creator A5061065977 @default.
• W4385705989 creator A5063931881 @default.
• W4385705989 creator A5065232101 @default.
• W4385705989 creator A5067708412 @default.
• W4385705989 creator A5068349233 @default.
• W4385705989 creator A5070138800 @default.
• W4385705989 creator A5080471083 @default.
• W4385705989 creator A5082339454 @default.
• W4385705989 creator A5084354003 @default.
• W4385705989 creator A5086809832 @default.
• W4385705989 creator A5088350515 @default.
• W4385705989 date "2023-08-01" @default.
• W4385705989 modified "2023-10-17" @default.
• W4385705989 title "P1147: FEASIBILITY AND OUTCOME AFTER DOSE REDUCTION OF IMMUNOCHEMOTHERAPY IN YOUNG ADULTS WITH BURKITT LYMPHOMA AND LEUKEMIA. RESULTS OF THE BURKIMAB14 TRIAL" @default.
• W4385705989 doi "https://doi.org/10.1097/01.hs9.0000971484.81356.4b" @default.
• W4385705989 hasPublicationYear "2023" @default.
• W4385705989 type Work @default.
• W4385705989 citedByCount "0" @default.
• W4385705989 crossrefType "journal-article" @default.
• W4385705989 hasAuthorship W4385705989A5001976783 @default.
• W4385705989 hasAuthorship W4385705989A5003682435 @default.
• W4385705989 hasAuthorship W4385705989A5005934312 @default.
• W4385705989 hasAuthorship W4385705989A5012303177 @default.
• W4385705989 hasAuthorship W4385705989A5018422609 @default.
• W4385705989 hasAuthorship W4385705989A5022583155 @default.
• W4385705989 hasAuthorship W4385705989A5023787291 @default.
• W4385705989 hasAuthorship W4385705989A5026012894 @default.
• W4385705989 hasAuthorship W4385705989A5027810280 @default.
• W4385705989 hasAuthorship W4385705989A5027815550 @default.
• W4385705989 hasAuthorship W4385705989A5028097465 @default.
• W4385705989 hasAuthorship W4385705989A5032225567 @default.
• W4385705989 hasAuthorship W4385705989A5034654830 @default.
• W4385705989 hasAuthorship W4385705989A5037711823 @default.
• W4385705989 hasAuthorship W4385705989A5041166124 @default.
• W4385705989 hasAuthorship W4385705989A5047316683 @default.
• W4385705989 hasAuthorship W4385705989A5048507239 @default.
• W4385705989 hasAuthorship W4385705989A5052872662 @default.
• W4385705989 hasAuthorship W4385705989A5058982311 @default.
• W4385705989 hasAuthorship W4385705989A5061065977 @default.
• W4385705989 hasAuthorship W4385705989A5063931881 @default.
• W4385705989 hasAuthorship W4385705989A5065232101 @default.
• W4385705989 hasAuthorship W4385705989A5067708412 @default.
• W4385705989 hasAuthorship W4385705989A5068349233 @default.
• W4385705989 hasAuthorship W4385705989A5070138800 @default.
• W4385705989 hasAuthorship W4385705989A5080471083 @default.
• W4385705989 hasAuthorship W4385705989A5082339454 @default.
• W4385705989 hasAuthorship W4385705989A5084354003 @default.
• W4385705989 hasAuthorship W4385705989A5086809832 @default.
• W4385705989 hasAuthorship W4385705989A5088350515 @default.
• W4385705989 hasBestOaLocation W43857059891 @default.
• W4385705989 hasConcept C126322002 @default.
• W4385705989 hasConcept C141071460 @default.
• W4385705989 hasConcept C143998085 @default.
• W4385705989 hasConcept C2776694085 @default.
• W4385705989 hasConcept C2778041864 @default.
• W4385705989 hasConcept C2779338263 @default.
• W4385705989 hasConcept C2780653079 @default.
• W4385705989 hasConcept C2781059491 @default.
• W4385705989 hasConcept C71924100 @default.
• W4385705989 hasConcept C90924648 @default.
• W4385705989 hasConceptScore W4385705989C126322002 @default.
• W4385705989 hasConceptScore W4385705989C141071460 @default.
• W4385705989 hasConceptScore W4385705989C143998085 @default.
• W4385705989 hasConceptScore W4385705989C2776694085 @default.
• W4385705989 hasConceptScore W4385705989C2778041864 @default.
• W4385705989 hasConceptScore W4385705989C2779338263 @default.
• W4385705989 hasConceptScore W4385705989C2780653079 @default.
• W4385705989 hasConceptScore W4385705989C2781059491 @default.
• W4385705989 hasConceptScore W4385705989C71924100 @default.
• W4385705989 hasConceptScore W4385705989C90924648 @default.
• W4385705989 hasLocation W43857059891 @default.
• W4385705989 hasOpenAccess W4385705989 @default.
• W4385705989 hasPrimaryLocation W43857059891 @default.
• W4385705989 hasRelatedWork W2002120878 @default.
• W4385705989 hasRelatedWork W2003938723 @default.
• W4385705989 hasRelatedWork W2047967234 @default.
• W4385705989 hasRelatedWork W2118496982 @default.

• next